Hematological Malignancies

Ibrutininb in Mantle cell

115 pts with MCL (bortezomib-naïve n=65; bortezomib-

exposed n=50); median age 68; median 3 (1-6)

prior therapies; 44% refractory

17.5 months estimated median response duration 13.9 months estimated median progression- free survival

Wang M et al. N Engl J Med 2013; 369: 507-516.